Chief Financial Officer
Andrew Drechsler brings more than 20 years of financial and life science industry experience to Provention and, as Chief Financial Officer, will be responsible for leading the company’s financial and capital markets activities.
Mr. Drechsler joins Provention after most recently serving as Chief Financial Officer of Insmed Incorporated, a publicly-traded biopharmaceutical company dedicated to improving the lives of patients with orphan pulmonary disease. During his tenure at Insmed, he helped the company raise in excess of $400 million through equity offerings. Prior to Insmed, Mr. Drechsler served as Chief Financial Officer for VaxInnate Corporation, a privately-held company that developed vaccines for infectious diseases, including seasonal and pandemic flu. There, he played a critical role in securing approximately $200 million in U.S. government funding for the company’s vaccine programs. Before joining VaxInnate, Mr. Drechsler served as Chief Financial Officer for Valera Pharmaceuticals where he helped Valera raise $35 million through an initial public offering.
Mr. Drechsler received a BS in Accountancy from Villanova University, graduating Magna Cum Laude. He obtained his Certified Public Accountant in the State of New Jersey and actively raises funds for and awareness of juvenile diabetes via the JDRF.